Alembic Pharmaceuticals Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Steady quarter, facility costs mask true earnings: Revenue grew 8% to ₹1,631 cr while net profit jumped 48% to ₹180 cr, but both are understated by a ₹64 cr P&L charge from a change in facility-expense accounting.
• US business is the turnaround story: The US generics segment grew 9% on 11 launches, new facilities are commercialized, and management sees a "little better" market with operating leverage ahead.
• API is the near-term drag: The API business de-grew 11% on lumpy customer offtake and will stay weak for "another quarter or two" before returning to regular growth.
• R&D spend is being reshaped, not cut: R&D stays at ~₹500 cr for the year but the mix is shifting away from OSD and Derm toward injectables and ophthalmics, with GLP-1 work now underway.
• What to watch next quarter: Whether the promised 5 Q4 US launches materialize, API offtake stabilizes, and ophthalmic and vial capacity utilization reaches practical levels within the 6-month timeline.

US Generics: The Turnaround Bet

• Market sentiment improving: Management described the US market as "looking a little better compared to where we were two years back, a year and a half back," with being a good supply partner still valued despite ongoing price erosion.
• Volume growth visible: US volumes increased on a nine-month basis compared to last year, driven by a broader portfolio and more products entering the market.
• Price erosion persists but varies widely: Erosion ranges from 5% to 30% product-to-product depending on the incumbent, though management declined to give a single blended number.
• Complex products as the moat: The strategy is shifting toward injectables, peptides, and oncology because incremental competition is much lower than in OSD, and complex products should see lesser price erosion and bigger product opportunities.
• New facilities now commercialized: All facilities are operational but capacity utilization is low; as more products launch, unabsorbed overheads will reduce and operating leverage will flow to margins.
• Launch cadence building: 11 products launched in Q3, at least 5 more expected in Q4, and 10 to 15 launches targeted for the next fiscal year.
• Long-term contracts still unresolved: Management is evaluating long-term US contracts but has not signed, citing fine-print concerns: "I don't like some of the fine print, hence I haven't jumped into it."

Pranav Amin: "The US business is looking better right now with new facilities already commercialized. As they ramp up, we will get a lot of operating leverage and cost improvements are also on track."

India & Animal Health: The Steady Earners

• India branded business resilient: Grew 9% to ₹596 cr despite muted demand in antibiotics and respiratory, the core acute segments. Specialty therapies including gynaecology, gastro, antidiabetic, and ophthalmology outpaced market growth.
• Acute segments held ground: Antibiotic and respiratory segments performed relatively better than the market, though on a higher base from Q3 of the prior year.
• Animal Health delivered a standout quarter: Grew 32%, described by management as a "fantastic quarter."
• New launches contributing: New product introductions in the domestic market continue to do well, supporting the specialty therapy outperformance.

API Business: The Lumpy Drag

• De-growth driven by timing, not demand destruction: API revenue fell 11% due to lower offtake from a few select customers, with management characterizing the business as inherently "lumpy" with large orders arriving every 3 to 5 quarters.
• Weakness to persist near-term: Management expects "another quarter or two" of lower API revenue before the business returns to its regular growth rate.
• Structurally sound despite the dip: The API business serves customers worldwide, carries good margins with decent EBITDA, and is not facing a fundamental demand problem.

R&D & Pipeline: Reshaping the Mix

• Spend level held steady: R&D was ₹114 cr in Q3 (7% of sales), and the full-year target of approximately ₹500 cr remains on track.
• Mix shifting toward complex dosage forms: OSD and Derm as a percentage of total R&D spend have come down, while injectables and ophthalmic are the growing areas, aligning with the US strategy toward complex products.
• GLP-1 entry underway: The company has started work on GLP-1 APIs and formulations, leveraging existing peptide capability, though launches are "still a little away" with filings yet to be completed.
• Pipeline activity healthy: 5 ANDAs filed in the quarter (cumulative 257), 7 approvals received, and 11 products launched.
• Segment-level R&D breakup withheld: Management declined to provide a breakup of R&D spend by dosage form or pipeline composition by segment, citing lumpiness and frequent changes.

Pranav Amin: "Yes that's an interesting area that is there. The P-4, the launches are still a little away but these are interesting APIs and formulations. We have got peptide capability as well. Hence we're looking at entering the segment, we started it so we can get some of the filings done and we'll see how it goes."

Margins & Costs: The Accounting Overhang

• Facility expensing change distorts comparability: From 1 January 2023, all expenses for new manufacturing facilities are charged to the P&L rather than capitalized. The Q3 impact was ₹64 cr in cash expenses and ₹14 cr in depreciation; the nine-month impact was ₹180 cr in cash expenses and ₹37 cr in depreciation.
• EBITDA and net profit understated: Reported EBITDA of ₹269 cr (16.5% of sales) and net profit growth of 48% to ₹180 cr are not exactly comparable with the prior year because of this accounting change.
• Other expenses contained: Other expenses excluding R&D were low in Q3, partly due to lower promotional spend versus Q2 and some savings on the raw material and sourcing side. Management indicated the numbers are in line and can be taken as a base.
• Operating leverage still to come: Capacity utilization across new facilities is low; as more products launch and CMO opportunities are pursued, unabsorbed overheads will reduce and flow through to margins.
• No further large CAPEX planned: Only maintenance CAPEX and some API expansion including GLP-1 and debottlenecking remain; the heavy international facility investment cycle is complete.

Ex-US & Other International

• Ex-US generics delivered exceptional growth: The quarter was described as "very satisfactory" for international business, with ex-US generics the standout performer.
• Large territories growing at ~15% CAGR: Europe, Canada, Australia, Brazil, and South Africa have grown at approximately 15% CAGR and management expects this trajectory to continue.
• Strategy distinct from the US: The ex-US approach differs from the US generics playbook, with a focus on these large territories as sustained growth drivers.

Guidance & Commitments

Key Metrics